View ValuationIXICO 将来の成長Future 基準チェック /06IXICOは、5.5%と1.8%でそれぞれ年率5.5%で利益と収益が成長すると予測される一方、EPSはgrowで38.7%年率。主要情報5.5%収益成長率38.68%EPS成長率Life Sciences 収益成長17.6%収益成長率1.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日08 Oct 2024今後の成長に関する最新情報お知らせ • May 21IXICO plc Reaffirms Earnings Guidance for the Full Year 2026IXICO plc reaffirmed earnings guidance for the full year 2026. For the year, the company remains focused on delivering on guidance of 15% revenue growth.お知らせ • Apr 22Ixico plc Provides Earnings Guidance for the First Half Ended 31 March 2026Ixico plc provided earnings guidance for the first half ended 31 March 2026. For the period, Revenues expected to be up 23% to £3.9 million (First half of 2025: £3.2m), driven by new contract wins, contract extensions and an increased volume of analyses in first half of 2026 relative to the equivalent prior period.お知らせ • Aug 14Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024Ixico plc provided revenue guidance for the year ending 30 September 2024. For the period, revenue is expected to be between £5.5 million and £5.9 million (2023: £6.7 million) reflecting growth of at least 20% in revenues across the second half of the year as compared to the first half (H1 2024: £2.5 million).お知らせ • Sep 29IXICO plc Provides Earnings Guidance for the Full Year of 2023IXICO plc provided earnings guidance for the full year of 2023. For the year, the company expects revenue to be £6.5 million (2022: £8.6 million). This reduction on the prior period principally reflects the final year of impact of the previously announced early cessation of large client trials coupled with some delays in new client trial initiations.お知らせ • May 10IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024IXICO plc provided earnings guidance for six months to 31 March 2023 and full year of 2024. for the period, revenues expected to be £3.2 million for six months to 31 March 2023 (H1 2022: £3.9 million); Loss before interest, tax, depreciation, and amortisation to 31 March 2023 expected to be £0.6 million (H1 2022: £0.5 million profit).The Board reaffirmed market guidance for the full year and return to revenue growth in 2024.お知らせ • Feb 07IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024IXICO plc provided revenue guidance for the year ending September 30, 2024. For the year, the company expects to achieve double digit revenue growth in the year to 30 September 2024. The Company has diversified its orderbook and the Board expects to see revenue growth in 2024 as it continues to build upon the contract and client wins of the last two years. This return to revenue growth will be a key step on the path back to profitability.すべての更新を表示Recent updatesお知らせ • May 21IXICO plc Reaffirms Earnings Guidance for the Full Year 2026IXICO plc reaffirmed earnings guidance for the full year 2026. For the year, the company remains focused on delivering on guidance of 15% revenue growth.お知らせ • May 13IXICO Plc Releases Latest Version Of AI-Driven Neuroimaging Technology PlatformIXICO plc announced the latest version (v.10) of IXI™, IXICO's proprietary AI enabled neuroimaging platform that delivers clinical trial imaging and biomarker insights in neurological disease research. The IXI™ 10.0 release brings advances in image reading precision and analysis, enables larger and faster image data processing, and integrates new tools for remote image access and data quality qualification. The latest generation of IXI™ lays the foundation for IXICO's technology to move beyond its traditional iCRO remit as part of the Group's TechBio strategy. The strategy is focused on increasing IXICO's addressable market by enabling external organizations to directly access IXICO's technology via licensing, technology integration and partnering models such as the recently announced collaboration with Medidata (26 March 2026). Designed by neuroscience and data science experts, the IXI™ Platform is a proprietary suit of technologies and AI tools tailor-made for neurological disease complexity. IXI™ uses machine learning and deep learning to reliably process data from global trials and build algorithms that precisely measure key imaging biomarkers associated with the identification, progression and treatment of Alzheimer's, Parkinson's, Huntington's and other rare neurological diseases. It is the only technology platform of its kind specifically built for, and exclusively focussed on, neuroimaging processing and neurological biomarker analysis. IXI™ is being used every day across the world. With over 30 cutting edge analytics algorithms the Platform integrates standardised high quality image data capture, image reading, advanced analysis and regulatorily compliant reporting of clinical data. IXI™ supports the biopharma industry to develop new medicines and diagnostic measures, informing decisions earlier in the drug development process via a single end to end platform.お知らせ • Apr 22Ixico plc Provides Earnings Guidance for the First Half Ended 31 March 2026Ixico plc provided earnings guidance for the first half ended 31 March 2026. For the period, Revenues expected to be up 23% to £3.9 million (First half of 2025: £3.2m), driven by new contract wins, contract extensions and an increased volume of analyses in first half of 2026 relative to the equivalent prior period.お知らせ • Apr 21IXICO plc to Report First Half, 2026 Results on May 19, 2026IXICO plc announced that they will report first half, 2026 results on May 19, 2026お知らせ • Apr 08IXICO plc has completed a Follow-on Equity Offering in the amount of £0.03032 million.IXICO plc has completed a Follow-on Equity Offering in the amount of £0.03032 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 379,000 Price\Range: £0.08 Transaction Features: Regulation Sお知らせ • Mar 31+ 1 more updateIXICO plc has filed a Follow-on Equity Offering in the amount of £10 million.IXICO plc has filed a Follow-on Equity Offering in the amount of £10 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 35,199,189 Price\Range: £0.08 Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 88,675,809 Price\Range: £0.08 Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 1,125,000 Price\Range: £0.08 Transaction Features: Regulation Sお知らせ • Feb 26IXICO plc Presents Automated Capabilities to Measure Brain Volume Loss on Magnetic Resonance Imaging (MRI) Within its IXI PlatformIXICO plc announced it has presented new demonstrating that automated capabilities to measure brain volume loss on magnetic resonance imaging (MRI) within its IXI Platform are at a minimum matching, and in some measures exceeding, the performance of semi-manual methods which require manual analysis by (human) experts. The accurate measurement of brain volume shrinkage (brain atrophy), caused by the loss of brain cells and the breakdown of connections between them, is fundamental to developing new treatments for a number of neurodegenerative diseases, including Huntington's Disease (HD). Traditionally, researchers have relied on a semi-manual approach to measure brain volume loss, known as the Boundary Shift Integral (BSI) which is currently considered to be the 'gold standard' method of analysis. In a recent study conducted by IXICO and a large US pharmaceutical partner, the results show that automated capabilities to measure brain atrophy on MRI within its IXI Platform match or exceed the performance of the semi-manual BSI method, providing an advanced, cost-effective and scalable solution to support clinical trials in HD. Of the three approaches evaluated to measure brain atrophy, IXICO demonstrated it was the most sensitive method for detecting whole brain and caudate (a small region deep in the brain impacted early in HD) volume loss.お知らせ • Feb 06IXICO plc Appoints Tanya Voloshen as Chief Commercial OfficerIXICO plc announced that it has appointed Tanya Voloshen as Chief Commercial Officer (CCO) based in Boston, Massachusetts (USA). Tanya joins IXICO from Perceptive Inc., a global contract research organisation (CRO) where she held the role as SVP Commercial. Prior to joining Perceptive, Tanya held senior commercial leadership roles for international clinical trial and medical technology companies with a focus on neuroscience and medical imaging including Clario (now part of Thermo Fisher Scientific), QMENTA and ConcertAI. Tanya started her career in the pharmaceutical industry working for Johnson & Johnson and Sanofi.お知らせ • Dec 09IXICO plc, Annual General Meeting, Jan 23, 2026IXICO plc, Annual General Meeting, Jan 23, 2026. Location: cct venues smithfield, two east poultry avenue, smithfield, ec1a 9pt, london United Kingdomお知らせ • Dec 01IXICO plc Announces Scientific Advisory Board Appointments, Effective December 1, 2025IXICO plc announced at the CTAD conference held on December 1, 2025, that it has appointed two leading global experts in the field of Alzheimer's Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO's advisory board with immediate Effective December 1, 2025. Michael Weiner, MD, is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, which is the largest observational study in the world concerning Alzheimer's Disease. He is the former Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center. His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer's disease and other brain disorders. Recently he has focused on developing voice agents for assessments in AD clinical trials. Michael is the Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, a 19-year national longitudinal study of over 3,500 subjects which is aimed at validating biomarkers for Alzheimer's disease at 63 sites across the USA and Canada for cognitive testing, MRI, PET, and lumbar puncture. He also launched the BrainHealthRegistry.org which is an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. This website registry recruits, screens, and longitudinally monitors brain function on more than 100,000 participants. Dr. Weiner has mentored over 200 postdoctoral fellows, has authored over 1000 peer reviewed research papers and 71 book chapters. Joanna is ais Professor of Applied Neuroimaging at the University of Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row Fogo Centre for research into Ageing and the Brain, and Consultant Neuroradiologist for NHS Lothian. Her work focuses on understanding the brain and its blood supply, and treatments to improve blood flow to the brain, including thrombolytic drugs that are now in routine use to treat stroke, and more recently treatments for small vessel disease and vascular dementia. Working with many colleagues, she has been instrumental in advancing understanding of the causes of cerebral small vessel disease and is now testing treatments in clinical trials. She has set up national research imaging facilities, co-ordinated international research networks, advanced stroke care worldwide and published over 1000 papers. A Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences, she has received awards from many UK and international brain and heart organizations and was made a Commander of the Order of the British Empire (CBE) for services to Medicine and Neuroscience in 2016.お知らせ • Nov 27IXICO plc to Report Fiscal Year 2025 Results on Dec 09, 2025IXICO plc announced that they will report fiscal year 2025 results on Dec 09, 2025お知らせ • Jun 10IXICO plc Announces FDA Clearance of New Alzheimer's Disease Blood Based Diagnostic BiomarkerIXICO plc outlined its role in the validation of a new Alzheimer's Disease (AD) diagnostic biomarker for client Fujirebio Diagnostics Inc. ("Fujirebio"), a global leader in the field of high-quality in vitro diagnostic (IVD) testing. The imaging analysis, conducted via IXICO's AI-driven platform, has supported Fujirebio's 510(k) FDA clearance for a new blood-based test that will help advance diagnosis and drug development in AD. The analysis included datasets from the Global Alzheimer's Platform Foundation's Bio-Hermes-001 study, of which both Fujirebio and IXICO are partners. As Bio-Hermes' imaging partner, IXICO led the standardisation, collection and expert analysis of PET data which served as the gold standard assessment of amyloid pathology in Fujirebio's FDA filing. On 16 May Fujirebio announced that it received clearance for its Lumipulse®? G pTau 217/b-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology In adult patients, aged 50 or older, being evaluated for Alzheimer's disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid the identification of patients with amyloid pathology associated with AD. Fujirebio's FDA clearance is based on data from a multi-center clinical study of 499 individuals in which amyloid positivity derived from the Lumipulse G pTau217/ss-Amyloid 1- 42 Plasma Ratio has been shown to be sufficiently comparable with results obtained through amyloid PET scan or CSF tests. These findings indicate that the new blood test can reliably predict the presence or absence of amyloid pathology associated with Alzheimer's disease at the time of the test in patients who are cognitively impaired. The test is intended for patients presenting at a specialized care setting with signs and symptoms of cognitive decline. The results must be interpreted in conjunction with other patient clinical information. The analysis by IXICO corresponds to the announcement made by the Company on 27 February 2025 that it had won a contract with an, at the time, undisclosed multinational biotechnology company. IXICO is now able to confirm that this company was Fujirebio. The imaging element of the clinical trial conducted on behalf of Fujirebio marks an expansion in IXICO's neuroimaging biomarker analyses capabilities beyond therapeutic clinical trial assessment to the analysis and validation of clinical diagnostic biomarkers.お知らせ • Apr 16+ 1 more updateIXICO plc to Report First Half, 2025 Results on May 20, 2025IXICO plc announced that they will report first half, 2025 results on May 20, 2025お知らせ • Dec 05IXICO plc, Annual General Meeting, Jan 24, 2025IXICO plc, Annual General Meeting, Jan 24, 2025. Location: ixicos office, 4th floor griffin court, 15 long lane, ec1a 9pn, london United Kingdomお知らせ • Nov 25IXICO plc to Report Fiscal Year 2024 Results on Dec 04, 2024IXICO plc announced that they will report fiscal year 2024 results on Dec 04, 2024お知らせ • Aug 14Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024Ixico plc provided revenue guidance for the year ending 30 September 2024. For the period, revenue is expected to be between £5.5 million and £5.9 million (2023: £6.7 million) reflecting growth of at least 20% in revenues across the second half of the year as compared to the first half (H1 2024: £2.5 million).お知らせ • Aug 05IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024IXICO plc announced that Bram Goorden will be appointed as Chief Executive Officer of the Company from 19 August 2024. Bram has over 20 years of leadership experience in BioPharma and precision medicine, serving in roles where he has been instrumental in shaping commercial strategies for scale, growing revenues and ultimately enabling the realisation of shareholder value. He has strong CNS experience, and established networks within IXICO's target market bringing sector relevant strength to IXICO. Bram joins having recently held C-level roles at Eagle Genomics Limited where he drove key industry alliances for their AI platform and NASDAQ listed SOPHiA Genetics Inc. where he expanded their US footprint and delivered key alliances with Pharma. In previous roles as VP International Business, he expanded Foundation Medicine Inc.'s global presence in precision medicine including programs with major BioPharma partners, and as division CEO of US-based Prometheus Laboratories he delivered shareholder value via the integration of the company into Nestle Health Science SA. Bram has also held senior management positions within UCB Pharma SA and Eli Lilly & Co, both in the field of CNS medicine. Bram's neuroscience experience is demonstrated at Board level through current and past roles at Mantis Photonics AB and Cerecin Inc. Bram started his career as a management consultant at Accenture. Bram's appointment follows the announcement made on 12 January 2024, of Giulio Cerroni's intention to retire from his role as CEO by the end of 2024. Giulio will step down as a director of the Company on 16 August 2024. Giulio continues to be available to the Company to support an orderly hand over.お知らせ • May 08IXICO plc to Report First Half, 2024 Results on May 21, 2024IXICO plc announced that they will report first half, 2024 results on May 21, 2024お知らせ • Jan 13Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024IXICO plc announced that Giulio Cerroni has informed the Board of his intention to retire from his role as Chief Executive Officer ("CEO") of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities. The Board has begun the process to appoint a new CEO in line with its succession plan and will update the market in due course.お知らせ • Jan 12Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024IXICO plc announced that Giulio Cerroni has informed the Board of his intention to retire from his role as director of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities.お知らせ • Dec 05IXICO plc, Annual General Meeting, Jan 25, 2024IXICO plc, Annual General Meeting, Jan 25, 2024, at 10:30 Coordinated Universal Time. Location: CCT Venues Smithfield, Two East Poultry Avenue, Smithfield, London United Kingdomお知らせ • Nov 27IXICO plc to Report Fiscal Year 2023 Results on Dec 05, 2023IXICO plc announced that they will report fiscal year 2023 results on Dec 05, 2023お知らせ • Oct 06Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit CommitteesIXICO plc announced the appointment of Dr. Dipti Amin as an Independent Non-Executive Director of the Company with immediate effect. Dr. Amin is an experienced non-executive director and medically trained senior executive with extensive commercial, leadership and operational experience, in medicine, pharmacology and the highly regulated healthcare and research sectors. Dr. Amin spent over twenty years of her executive career at IQVIA, occupying senior positions in compliance, drug safety and medical affairs and will bring significant additional pharmaceutical and CRO experience to the Company. Dr. Amin currently sits on the Boards of the University of Hertfordshire and Lineage Cell Therapeutics, a US based biotechnology company, having previously sat on the Boards of companies in both the private and public sectors. Dr. Amin will also be joining the Remuneration and Audit committees with immediate effect.お知らせ • Sep 29IXICO plc Provides Earnings Guidance for the Full Year of 2023IXICO plc provided earnings guidance for the full year of 2023. For the year, the company expects revenue to be £6.5 million (2022: £8.6 million). This reduction on the prior period principally reflects the final year of impact of the previously announced early cessation of large client trials coupled with some delays in new client trial initiations.お知らせ • May 11IXICO plc to Report First Half, 2023 Results on May 23, 2023IXICO plc announced that they will report first half, 2023 results on May 23, 2023お知らせ • May 10IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024IXICO plc provided earnings guidance for six months to 31 March 2023 and full year of 2024. for the period, revenues expected to be £3.2 million for six months to 31 March 2023 (H1 2022: £3.9 million); Loss before interest, tax, depreciation, and amortisation to 31 March 2023 expected to be £0.6 million (H1 2022: £0.5 million profit).The Board reaffirmed market guidance for the full year and return to revenue growth in 2024.お知らせ • Feb 07IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024IXICO plc provided revenue guidance for the year ending September 30, 2024. For the year, the company expects to achieve double digit revenue growth in the year to 30 September 2024. The Company has diversified its orderbook and the Board expects to see revenue growth in 2024 as it continues to build upon the contract and client wins of the last two years. This return to revenue growth will be a key step on the path back to profitability.お知らせ • Dec 07IXICO plc, Annual General Meeting, Jan 27, 2023IXICO plc, Annual General Meeting, Jan 27, 2023, at 10:30 Coordinated Universal Time. Location: CCT Venues Smithfield, Two East Poultry Avenue, Smithfield, London London United Kingdom業績と収益の成長予測OTCPK:PHYO.F - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20256-2-2-219/30/20246-2-2-213/31/20246-2-2-1N/A12/31/20236-2-20N/A9/30/20237-1-20N/A6/30/20237-1-11N/A3/31/202380-11N/A12/31/202281-11N/A9/30/202291-11N/A6/30/202281-11N/A3/31/202281-11N/A12/31/202191-11N/A9/30/202192-21N/A6/30/2021101-11N/A3/31/202110102N/A12/31/202010102N/A9/30/202010112N/A6/30/20209101N/A3/31/202091-10N/A12/31/201981-10N/A9/30/201980-10N/A6/30/201970-10N/A3/31/20196000N/A12/31/20186000N/A9/30/20185-100N/A6/30/20185-1N/AN/AN/A3/31/20185-100N/A12/31/20174-1N/A0N/A9/30/20174-2N/A-1N/A6/30/20174-2N/AN/AN/A3/31/20174-2N/A0N/A12/31/20164-2N/A-1N/A9/30/20163-2N/A-2N/A6/30/20163-2N/AN/AN/A3/31/20163-2N/A-2N/A12/31/20153-1N/A-1N/A9/30/20153-1N/A-1N/A3/31/20153-1N/A-1N/A12/31/20143-1N/A-2N/A9/30/20143-2N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PHYO.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PHYO.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: PHYO.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PHYO.Fの収益 ( 1.8% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: PHYO.Fの収益 ( 1.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PHYO.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/23 12:29終値2024/07/26 00:00収益2024/03/31年間収益2023/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IXICO plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Adam McCarterCavendishChristopher DonnellanCavendishHans Bjorn BostromEdison Investment Research1 その他のアナリストを表示
お知らせ • May 21IXICO plc Reaffirms Earnings Guidance for the Full Year 2026IXICO plc reaffirmed earnings guidance for the full year 2026. For the year, the company remains focused on delivering on guidance of 15% revenue growth.
お知らせ • Apr 22Ixico plc Provides Earnings Guidance for the First Half Ended 31 March 2026Ixico plc provided earnings guidance for the first half ended 31 March 2026. For the period, Revenues expected to be up 23% to £3.9 million (First half of 2025: £3.2m), driven by new contract wins, contract extensions and an increased volume of analyses in first half of 2026 relative to the equivalent prior period.
お知らせ • Aug 14Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024Ixico plc provided revenue guidance for the year ending 30 September 2024. For the period, revenue is expected to be between £5.5 million and £5.9 million (2023: £6.7 million) reflecting growth of at least 20% in revenues across the second half of the year as compared to the first half (H1 2024: £2.5 million).
お知らせ • Sep 29IXICO plc Provides Earnings Guidance for the Full Year of 2023IXICO plc provided earnings guidance for the full year of 2023. For the year, the company expects revenue to be £6.5 million (2022: £8.6 million). This reduction on the prior period principally reflects the final year of impact of the previously announced early cessation of large client trials coupled with some delays in new client trial initiations.
お知らせ • May 10IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024IXICO plc provided earnings guidance for six months to 31 March 2023 and full year of 2024. for the period, revenues expected to be £3.2 million for six months to 31 March 2023 (H1 2022: £3.9 million); Loss before interest, tax, depreciation, and amortisation to 31 March 2023 expected to be £0.6 million (H1 2022: £0.5 million profit).The Board reaffirmed market guidance for the full year and return to revenue growth in 2024.
お知らせ • Feb 07IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024IXICO plc provided revenue guidance for the year ending September 30, 2024. For the year, the company expects to achieve double digit revenue growth in the year to 30 September 2024. The Company has diversified its orderbook and the Board expects to see revenue growth in 2024 as it continues to build upon the contract and client wins of the last two years. This return to revenue growth will be a key step on the path back to profitability.
お知らせ • May 21IXICO plc Reaffirms Earnings Guidance for the Full Year 2026IXICO plc reaffirmed earnings guidance for the full year 2026. For the year, the company remains focused on delivering on guidance of 15% revenue growth.
お知らせ • May 13IXICO Plc Releases Latest Version Of AI-Driven Neuroimaging Technology PlatformIXICO plc announced the latest version (v.10) of IXI™, IXICO's proprietary AI enabled neuroimaging platform that delivers clinical trial imaging and biomarker insights in neurological disease research. The IXI™ 10.0 release brings advances in image reading precision and analysis, enables larger and faster image data processing, and integrates new tools for remote image access and data quality qualification. The latest generation of IXI™ lays the foundation for IXICO's technology to move beyond its traditional iCRO remit as part of the Group's TechBio strategy. The strategy is focused on increasing IXICO's addressable market by enabling external organizations to directly access IXICO's technology via licensing, technology integration and partnering models such as the recently announced collaboration with Medidata (26 March 2026). Designed by neuroscience and data science experts, the IXI™ Platform is a proprietary suit of technologies and AI tools tailor-made for neurological disease complexity. IXI™ uses machine learning and deep learning to reliably process data from global trials and build algorithms that precisely measure key imaging biomarkers associated with the identification, progression and treatment of Alzheimer's, Parkinson's, Huntington's and other rare neurological diseases. It is the only technology platform of its kind specifically built for, and exclusively focussed on, neuroimaging processing and neurological biomarker analysis. IXI™ is being used every day across the world. With over 30 cutting edge analytics algorithms the Platform integrates standardised high quality image data capture, image reading, advanced analysis and regulatorily compliant reporting of clinical data. IXI™ supports the biopharma industry to develop new medicines and diagnostic measures, informing decisions earlier in the drug development process via a single end to end platform.
お知らせ • Apr 22Ixico plc Provides Earnings Guidance for the First Half Ended 31 March 2026Ixico plc provided earnings guidance for the first half ended 31 March 2026. For the period, Revenues expected to be up 23% to £3.9 million (First half of 2025: £3.2m), driven by new contract wins, contract extensions and an increased volume of analyses in first half of 2026 relative to the equivalent prior period.
お知らせ • Apr 21IXICO plc to Report First Half, 2026 Results on May 19, 2026IXICO plc announced that they will report first half, 2026 results on May 19, 2026
お知らせ • Apr 08IXICO plc has completed a Follow-on Equity Offering in the amount of £0.03032 million.IXICO plc has completed a Follow-on Equity Offering in the amount of £0.03032 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 379,000 Price\Range: £0.08 Transaction Features: Regulation S
お知らせ • Mar 31+ 1 more updateIXICO plc has filed a Follow-on Equity Offering in the amount of £10 million.IXICO plc has filed a Follow-on Equity Offering in the amount of £10 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 35,199,189 Price\Range: £0.08 Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 88,675,809 Price\Range: £0.08 Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 1,125,000 Price\Range: £0.08 Transaction Features: Regulation S
お知らせ • Feb 26IXICO plc Presents Automated Capabilities to Measure Brain Volume Loss on Magnetic Resonance Imaging (MRI) Within its IXI PlatformIXICO plc announced it has presented new demonstrating that automated capabilities to measure brain volume loss on magnetic resonance imaging (MRI) within its IXI Platform are at a minimum matching, and in some measures exceeding, the performance of semi-manual methods which require manual analysis by (human) experts. The accurate measurement of brain volume shrinkage (brain atrophy), caused by the loss of brain cells and the breakdown of connections between them, is fundamental to developing new treatments for a number of neurodegenerative diseases, including Huntington's Disease (HD). Traditionally, researchers have relied on a semi-manual approach to measure brain volume loss, known as the Boundary Shift Integral (BSI) which is currently considered to be the 'gold standard' method of analysis. In a recent study conducted by IXICO and a large US pharmaceutical partner, the results show that automated capabilities to measure brain atrophy on MRI within its IXI Platform match or exceed the performance of the semi-manual BSI method, providing an advanced, cost-effective and scalable solution to support clinical trials in HD. Of the three approaches evaluated to measure brain atrophy, IXICO demonstrated it was the most sensitive method for detecting whole brain and caudate (a small region deep in the brain impacted early in HD) volume loss.
お知らせ • Feb 06IXICO plc Appoints Tanya Voloshen as Chief Commercial OfficerIXICO plc announced that it has appointed Tanya Voloshen as Chief Commercial Officer (CCO) based in Boston, Massachusetts (USA). Tanya joins IXICO from Perceptive Inc., a global contract research organisation (CRO) where she held the role as SVP Commercial. Prior to joining Perceptive, Tanya held senior commercial leadership roles for international clinical trial and medical technology companies with a focus on neuroscience and medical imaging including Clario (now part of Thermo Fisher Scientific), QMENTA and ConcertAI. Tanya started her career in the pharmaceutical industry working for Johnson & Johnson and Sanofi.
お知らせ • Dec 09IXICO plc, Annual General Meeting, Jan 23, 2026IXICO plc, Annual General Meeting, Jan 23, 2026. Location: cct venues smithfield, two east poultry avenue, smithfield, ec1a 9pt, london United Kingdom
お知らせ • Dec 01IXICO plc Announces Scientific Advisory Board Appointments, Effective December 1, 2025IXICO plc announced at the CTAD conference held on December 1, 2025, that it has appointed two leading global experts in the field of Alzheimer's Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO's advisory board with immediate Effective December 1, 2025. Michael Weiner, MD, is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, which is the largest observational study in the world concerning Alzheimer's Disease. He is the former Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center. His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer's disease and other brain disorders. Recently he has focused on developing voice agents for assessments in AD clinical trials. Michael is the Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, a 19-year national longitudinal study of over 3,500 subjects which is aimed at validating biomarkers for Alzheimer's disease at 63 sites across the USA and Canada for cognitive testing, MRI, PET, and lumbar puncture. He also launched the BrainHealthRegistry.org which is an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. This website registry recruits, screens, and longitudinally monitors brain function on more than 100,000 participants. Dr. Weiner has mentored over 200 postdoctoral fellows, has authored over 1000 peer reviewed research papers and 71 book chapters. Joanna is ais Professor of Applied Neuroimaging at the University of Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row Fogo Centre for research into Ageing and the Brain, and Consultant Neuroradiologist for NHS Lothian. Her work focuses on understanding the brain and its blood supply, and treatments to improve blood flow to the brain, including thrombolytic drugs that are now in routine use to treat stroke, and more recently treatments for small vessel disease and vascular dementia. Working with many colleagues, she has been instrumental in advancing understanding of the causes of cerebral small vessel disease and is now testing treatments in clinical trials. She has set up national research imaging facilities, co-ordinated international research networks, advanced stroke care worldwide and published over 1000 papers. A Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences, she has received awards from many UK and international brain and heart organizations and was made a Commander of the Order of the British Empire (CBE) for services to Medicine and Neuroscience in 2016.
お知らせ • Nov 27IXICO plc to Report Fiscal Year 2025 Results on Dec 09, 2025IXICO plc announced that they will report fiscal year 2025 results on Dec 09, 2025
お知らせ • Jun 10IXICO plc Announces FDA Clearance of New Alzheimer's Disease Blood Based Diagnostic BiomarkerIXICO plc outlined its role in the validation of a new Alzheimer's Disease (AD) diagnostic biomarker for client Fujirebio Diagnostics Inc. ("Fujirebio"), a global leader in the field of high-quality in vitro diagnostic (IVD) testing. The imaging analysis, conducted via IXICO's AI-driven platform, has supported Fujirebio's 510(k) FDA clearance for a new blood-based test that will help advance diagnosis and drug development in AD. The analysis included datasets from the Global Alzheimer's Platform Foundation's Bio-Hermes-001 study, of which both Fujirebio and IXICO are partners. As Bio-Hermes' imaging partner, IXICO led the standardisation, collection and expert analysis of PET data which served as the gold standard assessment of amyloid pathology in Fujirebio's FDA filing. On 16 May Fujirebio announced that it received clearance for its Lumipulse®? G pTau 217/b-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology In adult patients, aged 50 or older, being evaluated for Alzheimer's disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid the identification of patients with amyloid pathology associated with AD. Fujirebio's FDA clearance is based on data from a multi-center clinical study of 499 individuals in which amyloid positivity derived from the Lumipulse G pTau217/ss-Amyloid 1- 42 Plasma Ratio has been shown to be sufficiently comparable with results obtained through amyloid PET scan or CSF tests. These findings indicate that the new blood test can reliably predict the presence or absence of amyloid pathology associated with Alzheimer's disease at the time of the test in patients who are cognitively impaired. The test is intended for patients presenting at a specialized care setting with signs and symptoms of cognitive decline. The results must be interpreted in conjunction with other patient clinical information. The analysis by IXICO corresponds to the announcement made by the Company on 27 February 2025 that it had won a contract with an, at the time, undisclosed multinational biotechnology company. IXICO is now able to confirm that this company was Fujirebio. The imaging element of the clinical trial conducted on behalf of Fujirebio marks an expansion in IXICO's neuroimaging biomarker analyses capabilities beyond therapeutic clinical trial assessment to the analysis and validation of clinical diagnostic biomarkers.
お知らせ • Apr 16+ 1 more updateIXICO plc to Report First Half, 2025 Results on May 20, 2025IXICO plc announced that they will report first half, 2025 results on May 20, 2025
お知らせ • Dec 05IXICO plc, Annual General Meeting, Jan 24, 2025IXICO plc, Annual General Meeting, Jan 24, 2025. Location: ixicos office, 4th floor griffin court, 15 long lane, ec1a 9pn, london United Kingdom
お知らせ • Nov 25IXICO plc to Report Fiscal Year 2024 Results on Dec 04, 2024IXICO plc announced that they will report fiscal year 2024 results on Dec 04, 2024
お知らせ • Aug 14Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024Ixico plc provided revenue guidance for the year ending 30 September 2024. For the period, revenue is expected to be between £5.5 million and £5.9 million (2023: £6.7 million) reflecting growth of at least 20% in revenues across the second half of the year as compared to the first half (H1 2024: £2.5 million).
お知らせ • Aug 05IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024IXICO plc announced that Bram Goorden will be appointed as Chief Executive Officer of the Company from 19 August 2024. Bram has over 20 years of leadership experience in BioPharma and precision medicine, serving in roles where he has been instrumental in shaping commercial strategies for scale, growing revenues and ultimately enabling the realisation of shareholder value. He has strong CNS experience, and established networks within IXICO's target market bringing sector relevant strength to IXICO. Bram joins having recently held C-level roles at Eagle Genomics Limited where he drove key industry alliances for their AI platform and NASDAQ listed SOPHiA Genetics Inc. where he expanded their US footprint and delivered key alliances with Pharma. In previous roles as VP International Business, he expanded Foundation Medicine Inc.'s global presence in precision medicine including programs with major BioPharma partners, and as division CEO of US-based Prometheus Laboratories he delivered shareholder value via the integration of the company into Nestle Health Science SA. Bram has also held senior management positions within UCB Pharma SA and Eli Lilly & Co, both in the field of CNS medicine. Bram's neuroscience experience is demonstrated at Board level through current and past roles at Mantis Photonics AB and Cerecin Inc. Bram started his career as a management consultant at Accenture. Bram's appointment follows the announcement made on 12 January 2024, of Giulio Cerroni's intention to retire from his role as CEO by the end of 2024. Giulio will step down as a director of the Company on 16 August 2024. Giulio continues to be available to the Company to support an orderly hand over.
お知らせ • May 08IXICO plc to Report First Half, 2024 Results on May 21, 2024IXICO plc announced that they will report first half, 2024 results on May 21, 2024
お知らせ • Jan 13Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024IXICO plc announced that Giulio Cerroni has informed the Board of his intention to retire from his role as Chief Executive Officer ("CEO") of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities. The Board has begun the process to appoint a new CEO in line with its succession plan and will update the market in due course.
お知らせ • Jan 12Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024IXICO plc announced that Giulio Cerroni has informed the Board of his intention to retire from his role as director of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities.
お知らせ • Dec 05IXICO plc, Annual General Meeting, Jan 25, 2024IXICO plc, Annual General Meeting, Jan 25, 2024, at 10:30 Coordinated Universal Time. Location: CCT Venues Smithfield, Two East Poultry Avenue, Smithfield, London United Kingdom
お知らせ • Nov 27IXICO plc to Report Fiscal Year 2023 Results on Dec 05, 2023IXICO plc announced that they will report fiscal year 2023 results on Dec 05, 2023
お知らせ • Oct 06Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit CommitteesIXICO plc announced the appointment of Dr. Dipti Amin as an Independent Non-Executive Director of the Company with immediate effect. Dr. Amin is an experienced non-executive director and medically trained senior executive with extensive commercial, leadership and operational experience, in medicine, pharmacology and the highly regulated healthcare and research sectors. Dr. Amin spent over twenty years of her executive career at IQVIA, occupying senior positions in compliance, drug safety and medical affairs and will bring significant additional pharmaceutical and CRO experience to the Company. Dr. Amin currently sits on the Boards of the University of Hertfordshire and Lineage Cell Therapeutics, a US based biotechnology company, having previously sat on the Boards of companies in both the private and public sectors. Dr. Amin will also be joining the Remuneration and Audit committees with immediate effect.
お知らせ • Sep 29IXICO plc Provides Earnings Guidance for the Full Year of 2023IXICO plc provided earnings guidance for the full year of 2023. For the year, the company expects revenue to be £6.5 million (2022: £8.6 million). This reduction on the prior period principally reflects the final year of impact of the previously announced early cessation of large client trials coupled with some delays in new client trial initiations.
お知らせ • May 11IXICO plc to Report First Half, 2023 Results on May 23, 2023IXICO plc announced that they will report first half, 2023 results on May 23, 2023
お知らせ • May 10IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024IXICO plc provided earnings guidance for six months to 31 March 2023 and full year of 2024. for the period, revenues expected to be £3.2 million for six months to 31 March 2023 (H1 2022: £3.9 million); Loss before interest, tax, depreciation, and amortisation to 31 March 2023 expected to be £0.6 million (H1 2022: £0.5 million profit).The Board reaffirmed market guidance for the full year and return to revenue growth in 2024.
お知らせ • Feb 07IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024IXICO plc provided revenue guidance for the year ending September 30, 2024. For the year, the company expects to achieve double digit revenue growth in the year to 30 September 2024. The Company has diversified its orderbook and the Board expects to see revenue growth in 2024 as it continues to build upon the contract and client wins of the last two years. This return to revenue growth will be a key step on the path back to profitability.
お知らせ • Dec 07IXICO plc, Annual General Meeting, Jan 27, 2023IXICO plc, Annual General Meeting, Jan 27, 2023, at 10:30 Coordinated Universal Time. Location: CCT Venues Smithfield, Two East Poultry Avenue, Smithfield, London London United Kingdom